1. Scrip
  2. >>New Products

Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK

 
• By Sten Stovall

The promise seen in Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, should offset payer and HTA reluctance to use the monoclonal antibody despite its conditional EU marketing approval status.

The granting of conditional marketing authorization to Eli Lilly & Co.'s Lartruvo (olaratumab) by the EU Commission for the initial treatment of soft tissue sarcoma reflects the unmet need for the condition and growing flexibility shown by regulators to promising orphan drugs, forces that should combine into an acceptance of the drug by payers and regional health technology agencies in the region, analysts say.

Lartruvo's formal approval on Nov. 11 follows a recommendation for conditional marketing authorization from the European Medicines Agency in September as a new treatment for soft tissue sarcoma (STS). (Also see "Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System" - Pink Sheet, 26 September, 2016.) Having been designated as an orphan medicinal product by the EMA on Feb

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip